Casefinding Flashcards
7 cards from real CTR practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Casefinding flashcards as text
Which ICD-10-CM code range indicates a primary malignant neoplasm and is a key target during casefinding?
Answer: C00–C96 – Malignant neoplasms
ICD-10-CM codes C00–C96 represent primary malignant neoplasms and are the primary codes targeted in diagnosis-index casefinding.
When casefinding from the radiation oncology department, which document is the BEST primary source to identify new cancer cases?
Answer: Simulation and treatment planning records
Simulation and treatment planning records document the specific site being treated and the cancer diagnosis, making them the most useful primary casefinding source in radiation oncology.
A registrar is conducting casefinding and finds a patient who had a positive fine needle aspiration (FNA) biopsy for malignancy performed at the facility but received all treatment elsewhere. Is this case reportable?
Answer: Yes, as an analytic case because diagnosis was made at the facility
A case is analytic when the diagnosing facility is your own, even if treatment occurs elsewhere; diagnosis at the facility makes it a Class 1 analytic case.
What is the purpose of casefinding audits in a cancer registry program?
Answer: To verify completeness and identify missed reportable cases
Casefinding audits assess whether all reportable cases are being captured and identify gaps in the casefinding process.
Squamous cell carcinoma of the skin is diagnosed and treated at your facility. How is this handled for registry purposes?
Answer: Not reportable under ACOS CoC standards
Squamous cell carcinoma of the skin (except lip) is excluded from reportability under ACOS CoC standards, similar to basal cell carcinoma.
A hospital registrar is reviewing the hematology/oncology clinic schedules for casefinding. A new patient has a diagnosis of 'myelodysplastic syndrome.' Is this reportable?
Answer: Yes, MDS is a reportable hematopoietic neoplasm
Myelodysplastic syndrome (MDS) is a reportable hematopoietic neoplasm per SEER and ACOS CoC guidelines.
Which of the following best describes a 'suspense system' in cancer registry casefinding?
Answer: A list of cases pending pathology confirmation before abstracting
A suspense system holds potential cases identified from logs or schedules until pathology or other confirmation is received, ensuring no cases are missed.
How this page was made: written with AI tools and published by Nathan Beja, founder of Practice Test Geeks, who is responsible for its content. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy
Sources & references
Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy
- ncra-usa.org — Renewal, eligibility, passing score, retake policy, score release, test dates, time limit, test delivery, fees, registration deadline · verified Oct 2026